Close Menu

sepsis

A consortium led by the Barcelona-based company recently received €150,000 in EU funding to bring the platform to market.

The firm is completing a clinical study that it hopes will facilitate the launch of its AST system that provides results in four hours after a positive blood culture.

The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.

 

The company has also seen uptake of HemoScreen in Europe and Australia since PixCell began selling the portable hematology analyzer in those markets.

The company's RaPID platform detects infections directly from a blood sample and can provide results in three hours.

The firm reissued its full-year guidance and said it expects to sell 60 instruments in the US  for the remainder of the year.

The firm also announced two new instruments that would diversify its product offerings.

The prize, organized by the British innovation foundation Nesta, has assembled a series of workshops and support sessions to help prize competitors. 

Intalere member hospitals will receive access to Magnolia's alliance member pricing and clinical performance guarantee for Steripath under the agreement.

Sepset said its early test for sepsis, a condition that requires rapid diagnosis and treatment, would give clinicians valuable time to identify treatment strategies.

Pages